Pfizer’s fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer’s investment outlook and what to watch going forward.
Analyst commentary on Pfizer in recent months has reflected both confidence in the company’s strategic positioning and execution, as well as continued recognition of ongoing challenges within the broader biopharma sector.
🐂 Bullish Takeaways
Scotiabank initiated coverage on several large cap drugmakers, including Pfizer, with an “Outperform” rating. The firm cites a sector-wide underperformance as creating an attractive entry point ahead of the next innovation wave. While Johnson & Johnson is their top pick, Pfizer is highlighted among other favored names benefitting from strong execution and a potential for future cures.
BofA raised its price target for Pfizer to $30 from $28, pointing to recent sector developments and fundamental changes as drivers for the partial re-rating of large cap biopharma companies. This reflects upward momentum in valuation and acknowledgment of positive pipeline developments.
BofA also noted that Pfizer’s recent agreement to acquire Metsera delivers an “impressive obesity portfolio,” expanding its pipeline with new assets like MET-097i, a next-generation GLP1 therapy moving toward Phase 3 trials. Such acquisitions are seen as enhancing Pfizer’s growth prospects.
Oppenheimer remarked that Pfizer’s collaboration with Olema Oncology is strategically significant, suggesting that its partnerships and clinical trial participation could position the company favorably for future growth opportunities, depending on clinical outcomes.
Jefferies referred to recent policy developments as a “win for Pharma” and cast Pfizer among large-cap firms well positioned, given ongoing investments in U.S. manufacturing infrastructure.
🐻 Bearish Takeaways
BofA flagged “significant uncertainty” regarding the timelines for vepdegestrant (vepdeg) commercialization after Pfizer and Arvinas announced seeking a partner for further development. This led BofA to downgrade Arvinas, reflecting the drag on expectations for the therapy but also introducing risk and potential delays relevant for Pfizer’s pipeline visibility.
Stephens lowered its estimate for peak sales attributed to vepdeg due to increased uncertainty and the decision to out-license, hinting at cautiousness around Pfizer’s near-term growth contributions from certain partnerships.
BofA maintains a Neutral rating on Pfizer’s shares despite the price target increase, signaling reservations about valuation and the extent to which upside may already be reflected in the stock.
Story continues
Overall, while analysts recognize Pfizer’s active pipeline management and strategic acquisitions as catalysts for future growth and improved valuation, there remains a degree of caution regarding near-term execution risks and the successful commercialization of new therapies.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!
NYSE:PFE Community Fair Values as at Nov 2025
Pfizer is pursuing the sale of its remaining stake in BioNTech for up to $508 million, marking the conclusion of one of the pandemic’s most lucrative collaborations.
The company has reached an agreement to acquire obesity drug developer Metsera for up to $10 billion after a competitive bidding process, reinforcing Pfizer’s presence in the growing weight-loss therapeutics market.
Pfizer reported positive clinical trial results, including improved survival rates for metastatic non-small cell lung cancer patients treated with BRAFTOVI plus MEKTOVI and notable survival benefits in muscle-invasive bladder cancer with PADCEV plus KEYTRUDA.
The U.S. Federal Trade Commission granted early termination of its review of Pfizer’s pending Metsera acquisition, bringing the deal closer to completion.
Fair Value Estimate has risen slightly, increasing from $28.86 to $29.08 per share.
Discount Rate has edged higher, moving from 6.78% to 6.96%.
Revenue Growth projections have fallen further into negative territory, changing from -2.25% to -2.66%.
Net Profit Margin has decreased slightly, from 21.55% to 21.34%.
Future P/E (Price-to-Earnings) Ratio has increased moderately, from 15.70x to 16.54x.
A Narrative is a living story that connects the numbers, like fair value and future earnings, to the real business events shaping a company’s future. Narratives on Simply Wall St let investors voice their perspectives and forecasts, linking Pfizer’s journey to financial outcomes in a way that is easy to follow. Millions use these dynamic Narratives, updated when news or results are released, to decide when to buy or sell by comparing Fair Value to Price. All of this is accessible through the Simply Wall St Community page.
Discover why following the original Pfizer Narrative can give you an edge:
Stay ahead on developments in Pfizer’s expanding oncology and obesity drug pipelines, which could unlock transformative growth.
See how strategic digitalization and a focus on emerging markets are driving operational efficiency and opening new revenue opportunities.
Understand real-world risks from regulation, competition, and patent expirations, and how they impact Pfizer’s fair value as news breaks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PFE.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com